Product Description
Rimacalib (SMP 114) is a Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor, with IC50s of ~1 ?M for CaMKII? to ~30 ?M for CaMKII?.
Mechanisms of Action: CAMK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2005-003436-21 |
ASPECTS- Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment with SMP-114 | P2 |
Terminated |
Arthritis, Rheumatoid |
2007-11-26 |
2025-05-23 |
Treatments |
|
NCT00296257 |
D2450174 | P2 |
Terminated |
Arthritis, Rheumatoid |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|